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-Cell replacement therapy’s great
promise is that it can safely
and effectively restore insulin-
independent euglycemia to indi-
viduals with diabetes. Although difﬁcult
and expensive, modern insulin-based
treatment for type 1 diabetes has lead to
remarkable improvements in disease
prognosis (1–3). Based on recent popula-
tion-based epidemiological studies, we
have estimated that an individual diag-
nosed with type 1 diabetes today faces an
excess mortality over the next 20 years of
2% or 0.1% per year (4). Even indi-
viduals with long-standing type 1 diabe-
tessufﬁcientlyproblematictobelistedfor
a pancreas transplant have an annual
mortality 2.0% per year (5). The per-
ceived weaknesses associated with inten-
sive insulin therapy are its cost estimated
in1996tobe116,000USDoveralifetime
(6) and its inconvenience requiring me-
ticulous attention to diet, exercise, fre-
quent daily blood glucose measurements,
and multiple daily injections. In addition,
insulin therapy carries with it an in-
creased risk of serious hypoglycemia (1).
We attempt to address whether current
-cell replacement therapies overcome
theshortcomingsassociatedwithmedical
management. Certainly, -cell replace-
menttherapyshouldnotincreasethesub-
jects’ risk above that associated with
standard clinical care.
For patients with type 1 diabetes and
end-stage kidney disease, simultaneous
pancreas-kidney (SPK) transplantation has
appropriatelyachievedstandardofcaresta-
tus. SPK recipients can reasonably expect
improved and sustained insulin-indepen-
dent metabolic control, and the surgery
demonstrably improves survival rates com-
pared with those medically treated (5).
However,theoptionsaremuchlessclearfor
subjects with long-standing diabetes and
preserved kidney function deﬁned as a se-
rum creatinine 2.0 mg/dl. (And with
modern therapies, an ever-decreasing mi-
nority will develop renal failure.) For such
patients,pancreastransplantalone(PTA)or
pancreas-after-kidney (PAK) transplanta-
tion, despite reasonable insulin-indepen-
dence rates, does not improve survival and
mayevenincreasemortality(5).Theunder-
lying cause of the apparent excess mortality
post–pancreastransplantationisnotknown
butislikelycausedbythechronicimmuno-
suppressionrequiredtopreventallograftre-
jection and the nephrotoxicity associated
with that therapy. Impaired kidney func-
tion is, after all, a known major risk factor
for cardiovascular disease and excess mor-
talityindiabetes(7–10).Theaccompanying
editorialbyMineoetal.(11)citesastudyby
Gruessner et al. (12) that reports an 13%
mortality in subjects awaiting PTA. Our
analysis using the same national data
showed that the 4-year mortality for such
patients was much less (7.9%) (5). One
plausible explanation for the difference be-
tween the two studies, both of which used
the same United Network for Organ Shar-
ing (UNOS) data, is that our analysis ex-
cluded patients with impaired renal
function (serum creatinine 2.0 mg/dl)
while the report from Gruessner et al. did
not, and renal insufﬁciency is known to in-
crease subject mortality. We suspect that
our observation suggesting that solitary
whole pancreas transplantation may actu-
ally increase mortality risk has resulted in a
consistent decline in such procedures (PTA
plus PAK) performed in the U.S. in the past
5 years (Fig. 1).
Islet transplantation
Isolated islet transplantation has been
proposed as an alternative for these pa-
tients because it has at least two potential
advantages. First, by transplanting only
the islets required for insulin secretion,
one avoids many surgical and postopera-
tive complications associated with whole
pancreas transplantation. Second, at least
theoretically, islets can be isolated from
organs otherwise deemed unsuitable for
whole organ transplantation.
Unfortunately, subsequent experi-
ence has considerably dampened the tre-
mendous enthusiasm that accompanied
the “Edmonton Protocol” in 2000 (13)
that reported that seven out of seven iso-
lated islet transplant recipients main-
tained insulin-independent euglycemia
for at least 1 year. More extensive experi-
ence from several centers worldwide
(14–16) and a more prolonged follow-up
from the Edmonton group have exposed
several problems (17).
Insufﬁcient safety
Immunosuppression-related risks. All
islet transplant recipients must be immu-
nosuppressed to prevent graft rejection,
andsuchtherapyisassociatedwithsignif-
icant toxicity. Calcineurin phosphatase
inhibitors remain the mainstay of many
antirejection regimens, and the agents are
well known to progressively impair renal
function.Indeed,dependingontheorgan
transplanted, Ojo et al. (18) calculated
that7–21%willdeveloprenalfailure,and
early studies testing cyclosporine in indi-
viduals with recent-onset type 1 diabetes
were also marred by drug-induced de-
clines in renal function (19). Moreover,
tacrolimus and sirolimus (the antirejec-
tion agents originally used in the Edmon-
ton Protocol) are known to impair insulin
sensitivity (20) and islet vascularization
(21), and in vitro studies suggest direct
-cell toxicity (22). Tacrolimus is also as-
sociatedwithhypertensionandhypercho-
lesterolemia such that islet transplant
recipients more often require antihyper-
tensive and cholesterol-lowering medica-
tions following the transplantation
(14,17). Non–antigen-speciﬁc immuno-
suppression is also known to increase an
individual’s risk for malignancy. Of 325
islet allograft recipients entered into the
Clinical Islet Transplant Registry (CITR)
as of April 2008, 14 (4%) developed var-
ious neoplasms and, of these, four were
classiﬁed as possibly or deﬁnitely related
toimmunosuppression(14).Mostimpor-
tant, seven deaths have been reported
among the 325 CITR islet allograft recip-
ients (one because of viral meningitis
while on immunosuppression, ﬁve from
strokes [within 2–3 years postinfusion],
and three from unknown causes).
Some have argued that islet trans-
plantation represents an ideal clinical
model to test new immunosuppressive
regimens. We question that thinking.
Manyfactorscanleadtoisletallograftfail-
ure including islet graft quality, alloim-
mune rejection, recurrent anti–-cell
autoimmunity, and glucose or lipotoxic-
ity associated with the intrahepatic loca-
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(rev.in23).Andyet,clinicalinvestigators
lack assays for reliably predicting islet
qualityortoadequatelymonitoranti-islet
immune responses. We are unable to di-
agnose acute rejection (unlike kidney al-
lograft rejection) until the islet grafts have
failed, and rescue therapies do not exist.
With so many factors possibly contribut-
ing to graft failure, and considering our
inability to precisely measure the various
contributing factors, we argue it is difﬁ-
cult or impossible to critically assess a
new immunosuppressive regimen in the
islet transplant recipient. Further, we ar-
gue that immunosuppressive agents
shown to be effective and safe for one
indication generally transfer well to an-
other. Our point is that newer immuno-
modulatory strategies can be more
effectively tested in other transplant set-
tings (in particular, kidney transplanta-
tion); should safe and effective strategies
be identiﬁed, then testing that approach
in islet transplantation makes great sense.
Procedure-related complications. Al-
though isolated islet transplantation has
fewer acute complications than whole or-
gan transplantation, it is not free of seri-
ous complications. Procedure-related
events include hemorrhage, infections,
anemia,portalveinthrombosis,cholecys-
titis, and lymphopenia (0.06–0.36
events/person-year) (14). We acknowl-
edge that the rate of these acute compli-
cations has declined in recent years.
Insufﬁcient efﬁcacy
Following the initial enthusiasm regard-
ingtheEdmontonprotocol,ithasbecome
quite clear that long-term insulin inde-
pendence is infrequently attained. Only
10% of the recipients from the Edmon-
ton trial were still insulin independent 5
years following their transplant, while
only 14% of the islet allograft recipients
from the Immune Tolerance Network
(ITN) trial remained insulin independent
by 2 years following their procedure
(15,24,25). Twenty-three percent of the
islet allograft recipients reported to the
CITRwereinsulinindependentat2years;
however, most had multiple islet infu-
sions (14). These results stand in stark
contrast to those obtained in solid pan-
creas allograft recipients in whom the in-
sulin intendance rate at 5 years is nearly
threefold higher; thus, the glycemic con-
trol is better and more sustained and re-
quires only one donor pancreas (26,27),
whereas most islet allograft recipients re-
quireisletsfromtwoormoredonors.Fur-
thermore, in studies such as the ITN trial,
insulin independence was deﬁned rather
loosely(i.e.,“FBSnottoexceed140mg/dl
morethanthreetimes/weekand2-hpost-
prandialBG[bloodglucose]nottoexceed
180 mg/dl more than four times/week”).
This begs the question of why glycemic
thresholds for islet transplant recipients
should be any different than for the gen-
eral population. A key challenge facing
islet transplantation is this inexorable de-
cline in islet function that is presumably
secondary to auto- and alloimmune at-
tack, with perhaps other factors at play
such as immediate islet loss postinfusion
and poor revascularization postengraft-
ment (28,29). Although developments
such as anticoagulation to minimize the
immediate islet loss that occurs during
the infusion (30), alternate implantation
sites, or islet encapsulation may improve
islet survival, such potential advances
havenotbeenvalidatedinclinicaltrials.A
recentsmallseriesofﬁveconsecutivesub-
jects given a supplemental islet infusion,
then combination therapy with exenatide
and etanercept, reported sustained insu-
lin independence for up to 18 months
(31). These results are encouraging; how-
ever, the numbers are small and the fol-
low-up is short.
The most encouraging results cited in
the editorial by Mineo et al. such as from
astudybyVantyghemetal.(32)raisesev-
eral questions. First, Vantyghem et al.
(32)infusedmoreisletsthanmostgroups
(on average, islets from 2.7 donors/
recipient). The most straightforward
explanation for their high insulin inde-
pendence rate may be simply that better
early -cell function (conferred by trans-
planting more islets) predicts better late
islet function. Even so, islet transplanta-
tion is limited by its expense and the in-
sufﬁcient islet supply. If the protocol
employedbyVantyghemetal.waswidely
adopted(asdiscussedmorecompletelyin
the “Cost and availability” section), the
average cost for organs alone would in-
crease by 50,000 USD per patient and
the available organs will be spread more
thinly among potential recipients. Sec-
ond, the editorial by Mineo et al. states
that Vantyghem et al. achieved 5-year in-
sulinindependenceratesof57%.How-
ever, Vantyghem et al. only estimated
5-year graft survival from limited data; of
the 14 subjects in the study, only 7 had
reached the 3-year postislet transplant
time and only 3 reached the 4-year post-
transplant time period. We argue that
great care should be exercised when pro-
jectingresultsbasedonsuchlimiteddata.
Third, the islet transplant recipients in
this study lost creatinine clearance at a
rate of 1.8 ml   min
1   year
1 per 1.73
m
2. This rate of renal function loss is less
thanthosereportedbyothergroupsusing
the same immunosuppressive agents and
levels. In fact, therapeutic use of cal-
cineurin phosphatase inhibitors is invari-
ably associated with decreasing renal
function for the group receiving that
treatment. (Though within a treatment
group, some individuals seem more resis-
tant to the nephrotoxicity than others.) Is
there any reason to suspect that individ-
uals with type 1 diabetes who receive an
islet transplant are somehow resistant to
calcineurin inhibitor–induced nephro-
toxicity? Indeed, even Vantyghem et al.
report that of the 14 subjects in their
Figure 1—UNOS data showing that the number of SPK transplantation procedures performed
everyyearintheU.S.hasremainedstable.Thenumberofsolitarypancreastransplants(PTAand
PAK) performed has declined since the published report by Venstrom et al. (5) in 2003 showing
increased mortality in this group.
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uria following islet transplantation.
Islet transplantation improves
metabolic control, but at what cost?
Most islet transplant recipients retain
some graft function, i.e., continued circu-
lating C-peptide, for several years follow-
ing infusion (14,15,17,25). This partial
islet graft function serves to facilitate the
individual’s ability to achieve desired gly-
cemic control targets and to decrease the
frequency of severe hypoglycemic. Re-
ports also suggest an improved quality of
life (33,34). However, if this is the only
clinical gain from a complicated, expen-
sive procedure with signiﬁcant risks, is it
justiﬁed?
Islet transplantation and
complications
Renalfunction. Impairedrenalfunction
is a major determinant of cardiovascular
disease and mortality in patients with di-
abetes (7–10). Any new alternative ther-
apy for diabetes must reduce, and
certainlynothasten,therenaldiseasepro-
gression. Unfortunately, with some ex-
ceptions, most published clinical islet
(15,35) and whole pancreas transplanta-
tion studies have shown a progressive de-
cline in renal function in patients
following the procedure (18,36). In the 3
years following islet allograft transplanta-
tion, the participants in the Edmonton
trial had declining glomerular ﬁltration
rate (GFR) (on average, 0.39 ml   min
1  
month
1) and many had new or progres-
sive microalbuminuria (35). In the ITN
trial, the GFR also declined at a rate of
0.45 ml   min
1   month
1 (15). In com-
parison, the GFR declined at 0.114 ml  
min
1   month
1 in the Epidemiology of
Diabetes Interventions and Complica-
tions (EDIC) medically treated subjects
and at 0.183 ml   min
1   month
1 in
another study of subjects with long-
standing type 1 diabetes (36).
The principal criticism of the pub-
lished studies has been the lack of appro-
priate control groups to compare rates of
various end-organ complications. Re-
cently, Thompson and colleagues (37)
published their ﬁndings comparing islet
transplantation with intensive medical
therapy on the progression of type 1 dia-
betes–associated complications. The
crossover design study included 42 sub-
jects and was prospective but was non-
randomized and unblinded; patients
enrolled in an islet transplant protocol
were followed prior to and (for some) fol-
lowing their transplant. There was no sta-
tisticaldifferenceinrateofdeclineinGFR
before or after transplant; however, sub-
jects had a steeper decline in GFR while
on medical therapy (0.45 ml   min
1  
month
1)thanwaspredictedforthegen-
eral population (0.083 ml   min
1  
month
1). Interestingly, the rate of GFR
decline in this study’s medically treated
population was greater than rates previ-
ously reported for patients with long-
standing diabetes. Conversely, the
transplant recipients in this study experi-
enced a much slower GFR decline (0.12
ml   min
1   month
1) than had previ-
ously been described in other large clini-
cal -cell transplantation trials. The
results are intriguing but confusing given
that (except for the use of antithymocyte
globulin during induction) the antirejec-
tion therapy was not substantially different
from previous clinical islet transplantation
trials.
Retinopathy. Thomson and colleagues
(37) report that islet allograft recipients
appearedtohavelessprogressiveretinop-
athy. Although this ﬁnding is promising
and consistent with results following
pancreas transplantation (38,39), we
point out the study’s small size and state
that glycemic control following islet
transplant is not as persistent or physi-
ological as that following whole organ
transplantation.
Macrovascular complications. Islet
transplantation has not been shown to in-
ﬂuence cardiovascular disease given that
the islet recipient number remains rela-
tively small and the follow-up is short.
However, some of the immunosuppres-
sive agents commonly used to maintain
graft function in islet recipients are
known to raise blood pressure and cause
lipid abnormalities—two major risk fac-
tors for cardiovascular events. Further,
solitary pancreas transplantation, with
much higher rates of insulin indepen-
dence, has not been shown to improve
mortality, and some data suggest it may
actually worsen survival (5).
HLA sensitization. Most recipients re-
quire islets from multiple donors to
achieve insulin independence. Islets are
allocated based only on ABO compatibil-
ity,sorecipientsrisksensitizationtomul-
tiple HLA antigens. Indeed, Shapiro and
colleagues (40) recently reported that a
thirdofislettransplantrecipientsdevelop
anti–donor-speciﬁc HLA antibodies and
thatmostdevelopantibodiesagainstboth
class I and class II antigens. This group of
individuals will have fewer suitable do-
nors should, for example, renal replace-
ment therapy be required in the future.
Cost and availability
Clinical islet transplantation is an expen-
sive proposition. First-year expenses for a
typical procedure are estimated to be
150,000 USD (41): 20,000 USD for
hospital and follow-up visit charges,
30,000 USD for a year’s immunosuppres-
sive agents, and 100,000 USD for isolat-
ing islets because the charge for each
pancreas is about 25,000 USD, each re-
cipient requires, on average, islets from
two donors, and the islet isolation effort
succeeds only about half the time. (Thus,
four pancreata are typically required for
each recipient.) The lifetime cost is likely
to be much higher because the recipients
wouldrequireroutinemedicalvisitsasso-
ciated with immunosuppressive agent
complications, laboratory monitoring of
immunosuppressive drug levels, and
medical/surgical care for complications.
And given that most recipients continue
to take insulin, these costs are added to
the costs associated with routine diabetes
care. Aside from costs, broadly applying
islet transplantation is otherwise limited
by the supply of brain-dead donor organs
(currently only 8,000 per year in the
U.S.), inefﬁcient isolation techniques,
and the need for specialized centers to
perform the procedure. Indeed, Mineo et
al. argue for potential beneﬁt using pan-
creata from UNOS for islet transplanta-
tion; i.e., of the 8,000 donors available
each year, only 25% were used for
whole organ transplantation, leaving an
additional 6,000 organs that could be
used as a source for clinical islet trans-
plantationtrials.Andyet,giventhatorgan
procurement for clinical purposes man-
dates that each organ procured pay an
equalshareofallcostsrequired(25,000
USD for each organ procured) and if all
6,000 organs were procured for islet iso-
lation efforts, the annual cost for those
organs alone would be 6,000 times
$25,000 USD or 150,000,000 USD.
Clearly, such costs are difﬁcult to justify
during these ﬁscally constrained times.
Conclusion
Type 1 diabetes is a life-changing diagno-
sis that requires the patient’s nearly con-
stant attention. Although insulin therapy
is cumbersome, for most it can deliver
good metabolic control with resulting
protection from end-organ damage. Ad-
mittedly, multiple daily insulin injections
are difﬁcult for many, and over time, ap-
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ingly difﬁcult with more frequent and
severe hypoglycemia. -Cell replacement
could help overcome these difﬁculties.
Evenso,islettransplantationdoesnot(for
morethanafewyears)negatetheneedfor
insulinandtheassociatedinconveniences
and has not convincingly been shown to
favorably change the end-organ compli-
cation rate, at least with regard to the
kidney, which is the most signiﬁcant de-
terminant of patient survival. Moreover,
the transplantation procedure and subse-
quent immunosuppression have signiﬁ-
cant associated risks. Most concerning is
the worsening renal function observed in
islet recipients on immunosuppression,
but recipients also face increased risk of
infections, neoplasms, and deleterious
metabolicandcardiovasculareffects.Fur-
ther, islet transplantation is an expensive
therapy that cannot be widely applied be-
cause of limited supply of organs and
poor islet survival. Thus, there is little
clinical beneﬁt to be gained from clinical
islet transplantation, while there are nu-
merous serious concerns regarding its
safety and efﬁcacy. The risks associated
with islet transplantation lead us to con-
clude that it should only rarely, if ever, be
performed to improve metabolic control
or to reduce hypoglycemia risk. Rather,
wesuggestthatimprovedinsulindelivery
systemscanachievethesamegoalwithfar
less cost and minimal risk to nearly all
patients, and for those failing best efforts
using insulin, whole pancreas transplan-
tation remains the best “last resort”
therapy. We continue to enthusiastically
support ongoing research to overcome
the problems that at present shroud islet
transplantation’s great promise.
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